Publication Month: Jan 2021 | Report Code: TIPRE00016906 | No. of Pages: 160 | Category: Pharmaceuticals | Status: Published
Candida Auris is a fungus that causes a serious global health threat. It causes severe illness in hospitalized patients in several countries, including the US. Patients can remain colonized with C. Auris for a long time. Also, C. Auris can persist on surfaces in healthcare environments. This can result in the spread of C. Auris between patients in healthcare facilities. According to a CDC report of 2021, US cases of C. Auris have been found in patients who had recent stays in healthcare facilities in Egypt, India, Kenya, Kuwait, Pakistan, South Africa, South Korea, the UAE, and Venezuela, which also have documented cases. Thus, this can be a hospital-acquired infection. The emergence of Candida Auris is considered as one of the most serious problems associated with nosocomial transmission and infection control practices in the hospital environment. Additionally, the CDC stated that 560 cases of C. Auris infections were reported in the US as of January 31, 2019. Furthermore, despite execution of countermeasures to limit fungal infections in intensive care units (ICUs), cases continue to be observed and reported, with a tendency toward an endemic pattern. This shows the ability of C. Auris to persistent infection in the clinical environment, enabling its transmission within the critical care setting. Unlike other Candida species, C. Auris can colonize different anatomical sites (e.g., skin, axilla, rectum, and stool) and contaminate the hospital equipment and surfaces, creating a vicious cycle of spreading, acquisition, and infection, particularly in ICUs.
Additionally, according to an NCBI report published in Jan 2020, increasing number of travels to foreign countries and exposure to healthcare in countries with extensive C. Auris transmission as well as the higher flow of migrants, are factors that can contribute to the quick dissemination of this species. Further, a higher frequency of C. Auris was found in public hospitals as compared to the private ones, which may be connected to overcrowding and compromised infection control measures. Moreover, 7 out of every 1,000 patients admitted in ICUs across India are affected with a fungal infection, says preliminary analysis of data collected by researchers in Post Graduate Institute of Medical Education and Research, Chandigarh. The data was collected from 27 hospital ICUs across the country (11 government hospitals and 16 private hospitals). Thus, increasing incidence of hospital-acquired fungal infection is creating the demand for drugs that can prevent systemic aspergillosis and systemic candidiasis. This, in turn, is likely to boost the growth of the Systemic Aspergillosis and Systemic Candidiasis market
Get more information on this report :
Systemic aspergillosis and systemic candidiasis are types of fungal infections. Aspergillosis infection is caused by molds. It majorly affects the respiratory tract of an individual. It is a severe pulmonary infection caused by Aspergillus—a common fungus that affects people with weakened immune systems or lung diseases. Moreover, severe fungal infections occur due to other health problems, including asthma, cancer, AIDS, organ transplantation, and corticosteroid therapies. Early diagnosis allows prompt antifungal treatment; however, this is often delayed or unavailable, leading to severe chronic illness, death, or blindness. For instance, according to the Journal of Fungi published in March 2017, HIV/AIDS pandemic, tuberculosis, chronic obstructive pulmonary disease (COPD), asthma, and increasing incidence of cancers are the primary drivers of fungal infections in both developed and developing countries globally. Furthermore, a report published by the National Library of Medicine National Institutes of Health in October 2017 stated that ~3,000,000 cases of chronic pulmonary aspergillosis; ~223,100 cases of cryptococcal meningitis complicating HIV/AIDS; ~700,000 cases of invasive candidiasis; ~500,000 cases of Pneumocystis jirovecii pneumonia; ~250,000 cases of invasive aspergillosis; ~100,000 cases of disseminated histoplasmosis; over 10,000,000 cases of fungal asthma; and ~1,000,000 cases of fungal keratitis occur annually across the world. Moreover, according to a report by the Centers for Disease Control and Prevention (CDC), ~1,595 cases of Candida Auris have been observed in different states of the US.
Based on type, the systemic aspergillosis and systemic candidiasis market is segmented into voriconazole, liposomal amphotericin b, systemic oral azoles, topical antifungal agents, and others. In 2019, the systemic oral azoles segment held the largest share of the market. The same segment is expected to grow at the fastest rate during the forecast period owing to rising number of invasive fungal infections.
Get more information on this report :
Based on application, the global systemic aspergillosis and systemic candidiasis market is segmented into chronic pulmonary aspergillosis (CPA), allergic bronchopulmonary aspergillosis (ABPA), gastrointestinal candidiasis, genitourinary tract, candidiasis, and others. In 2019, the allergic bronchopulmonary aspergillosis (ABPA) segment held the largest share of the market. The same segment is expected to grow at the fastest rate during the forecast period.
|Market Size Value in||US$ 6,056.3 Million in 2019|
|Market Size Value by||US$ 8,247.5 Million by 2027|
|Growth rate||CAGR of 4.0% from 2020-2027|
|No. of Pages||160|
|No. of Tables||58|
|No. of Charts & Figures||70|
|Historical data available||Yes|
|Segments covered||Type ; Application , and Geography|
|Regional scope||North America, Europe, Asia Pacific, Middle East & Africa, South & Central America|
|Country scope||US, Canada, Mexico, UK, Germany, Spain, Italy, France, India, China, Japan, South Korea, Australia, UAE, Saudi Arabia, South Africa, Brazil, Argentina|
|Report coverage||Revenue forecast, company ranking, competitive landscape, growth factors, and trends|
|Free Sample Copy Available|
Product launches and approvals are the commonly adopted strategies by companies to expand their global footprints and product portfolios to meet the growing consumer demand. The systemic aspergillosis and systemic candidiasis market players are adopting the collaborations strategy to enlarge customer base worldwide, which also permits them to maintain their brand name globally.
The List of Companies - Systemic Aspergillosis and Systemic Candidiasis Market